Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Anticancer Agents.

Zamboni, William C; Charlab, Rosane; Burckart, Gilbert J; Stewart, Clinton F

Zamboni, William C; Charlab, Rosane; Burckart, Gilbert J; Stewart, Clinton F.

Afiliación

Zamboni WC; UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, Caroline Institute of Nanomedicine, University of North Carolina, Chapel Hill, NC, USA.
Charlab R; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Burckart GJ; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Stewart CF; St. Jude Children's Research Hospital, Memphis, TN, USA.

J Clin Pharmacol ; 63 Suppl 2: S85-S102, 2023 11.

Article en En | MEDLINE | ID: mdl-37942904

Asunto(s)

Antineoplásicos; Neoplasias; Obesidad Mórbida; Humanos; Antineoplásicos/uso terapéutico; Antineoplásicos/farmacocinética; Preparaciones Farmacéuticas; Neoplasias/tratamiento farmacológico; Desarrollo de Medicamentos; Farmacocinética

Palabras clave

clinical pharmacology (CPH); drug development; obesity; oncology (ONC); pharmacokinetics and drug metabolism

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Obesidad Mórbida / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: J Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google